PD-L1 status on circulating tumor cells: a promising predictor in advanced lung cancer with PD-1/PD-L1 immunotherapies
{{output}}
Background: Tumor heterogeneity and invasive sampling limit traditional tissue-based PD-L1 testing in advanced lung cancer. We explored a non-invasive alternative by assessing PD-L1 expression on circulating tumor cells (CTC PD-L... ...
